This article is more than 5 years old. Information may no longer be current.
Ophthalmic solution shows promise as dry eye treatment
Click Here to Manage Email Alerts
Diquafosol ophthalmic solution was found in a phase 2 study to be safe and effective in the treatment of dry eye syndrome.
The randomized, double-masked, multicenter, parallel-group, placebo-controlled trial analyzed 286 Japanese patients with dry eye; 96 patients received topical diquafosol 1%, 96 patients received topical diquafosol 3%, and 94 patients received placebo six times per day for 6 weeks after a 2-week washout period.
There were significant improvements in fluorescein corneal staining scores, the primary outcome measure, in both diquafosol groups compared with placebo at 4 weeks (P = .037 for 1% and P = .002 for 3%) and in rose bengal corneal and conjunctival staining scores (P = .007 for 1% and P = .004 for 3%).
There were significant improvements in subjective dry eye symptoms with both concentrations vs. placebo (P ≤ 0.033), and there were no significant differences regarding adverse events.
The trial featured the first testing of the 3% solution, and it was shown to be equally or more effective than the 1% solution, the authors said.
Click Here to Manage Email Alerts